title: Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome.
abstract: Oxidized low-density lipoprotein (oxLDL) is a key feature of the atheromatosus plaque and plays a critical role in foam cell formation and perpetuation of inflammatory processes. In antiphospholipid syndrome (APS), oxLDL molecules form complexes with beta2GPI and become target antigens for autoantibodies, which are detectable in the sera of these patients. oxLDL takes part in the pathogenesis of APS and in the concomitant accelerated atherosclerosis, yet the exact associated immune mechanisms are not clear in details. The aim of this study was to assess the activation and proliferation response of peripheral blood mononuclear cells (PBMCs) derived from patients with APS in the presence of oxLDL. Thirteen patients with APS and nine healthy individuals were enrolled in the study. Separated PBMCs of these patients were cultured in the presence of immunogenic epitope of oxLDL. Lymphocyte proliferation and cytokine secretion (TNF-alpha, IL-2, IFN-gamma, IL-4, and IL-10) were assessed by ELISA. We found significant PBMC proliferation in APS compared to healthy controls (PI/proliferation index/APS: 1.76 vs. PI control: 0.56; p = 0.032). A significant IL-2 and IFN-gamma secretion were detected upon oxLDL stimulus in patients with APS compared to controls (IL-2 cytokine secretion index (CSI) APS: 278.5, IL-2 CSI controls: 65.1; p = 0.025; IFN-gamma CSI APS: 163.2, IFN-gamma CSI controls: 77.4; p = 0.025). Based on our findings, we assume that oxLDL via Th1-type cytokine production and lymphocyte proliferation may contribute to the perpetuation of immune processes in APS.
authors.affiliation: Intensive Care Unit, 3rd Department of Medicine, Institute of Internal Medicine, University of Debrecen Medical and Health Science Center, Móricz Zs Street 22, 4004 Debrecen, Hungary. renata.laczik@gmail.com
authors.forename: Renata
authors.initials: R
authors.lastname: Laczik
authors.forename: Peter
authors.initials: P
authors.lastname: Szodoray
authors.forename: Katalin
authors.initials: K
authors.lastname: Veres
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lakos
authors.forename: Sandor
authors.initials: S
authors.lastname: Sipka
authors.forename: Gyula
authors.initials: G
authors.lastname: Szegedi
authors.forename: Pal
authors.initials: P
authors.lastname: Soltész
mesh_terms: D000328:Adult; D000368:Aged; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000276:immunology*; D050197:Atherosclerosis / Q000150:complications / Q000209:etiology / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008077:Lipoproteins, LDL / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D016207:Cytokines; D007376:Interleukin-2; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein